Please assess the completion status of the following clinical trial:

Trial Title: Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* BMI of 18 - 29.9 kg/m2~* have not used tobacco or nicotine containing products for at least 3 months prior to dosing~* be able to remain abstinent throughout the study.~Exclusion Criteria:~* History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.~* positive urine drug/alcohol testing~* Positive for HIV, HBsAg, HCV ab~* History of anaphylactic reaction to medicine or environmental exposure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 1.1 mcg/kg of HM10460A, placebo, or Neulasta
- Cohort 2 (Type: EXPERIMENTAL): 3.3 mcg/kg HM10460A, placebo or Neulasta
- Cohort 3 (Type: EXPERIMENTAL): 10 mcg/kg of HM10460A, placebo, or Neulasta
- Cohort 4 (Type: EXPERIMENTAL): 30 mcg/kg of HM10460A, placebo, or Neulasta
- Cohort 5 (Type: EXPERIMENTAL): 90 mcg/kg or HM10460A, placebo, or Neulasta
- Cohort 6 (Type: EXPERIMENTAL): 270 mcg/kg of HM10460A, placebo, or Neulasta

Based on this trial design, predict the completion outcome and termination type (if applicable).